Evidence map›Paper›PMID 40665692›Full record

ArticleJournal of Alzheimer's disease : JAD2025

Brain amyloid-β deposition, severity of subjective cognitive decline and gait speed in cognitively unimpaired oldest-old.

Neelesh K Nadkarni, Subashan Perera, Beth E Snitz, Brian J Lopresti, Marissa A Gogniat, Victor L Villemagne, Oscar L Lopez

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Neelesh K NadkarniDepartment of Medicine, Division of Geriatric Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Subashan PereraDepartment of Medicine, Division of Geriatric Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Beth E SnitzDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Brian J LoprestiDepartment of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
Marissa A GogniatDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Victor L VillemagneDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
Oscar L LopezDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.

Funding

Vascular Moderators of the Impact of Alzheimer's Pathology in the Young-OldP01AG025204 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN, Ann D. Cohen · 2005 to 2026
$56.5M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 1985 to 2019
$43.0M
GINKGO BILOBA PREVENTION TRIAL IN OLDER INDIVIDUALSU01AT000162 · NCCIH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOPEZ, OSCAR L. · 1999 to 2009
$34.7M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JENNIFER S BRACH · 2004 to 2026
$28.6M
AMYLOID PATHOLOGY AND COGNITION IN NORMAL ELDERLYR37AG025516 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KLUNK, WILLIAM E · 2005 to 2014
$4.3M
The Aging Brain and the Cognition-Mobility Interface in Clinically Normal Older AdultsK23AG049945 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NADKARNI, NEELESH K · 2015 to 2019
$769k
NCCIH NIH HHS U01 AT000162NIA NIH HHS K23 AG049945NIA NIH HHS P01 AG025204NIA NIH HHS P30 AG024827NIA NIH HHS P30 AG066468NIA NIH HHS P50 AG005133NIA NIH HHS R37 AG025516
6 · The paper itself

Abstract

BackgroundGait speed slows prior to cognitive decline in clinical Alzheimer's disease (AD), and is associated with cognitive performance and biomarkers of amyloid-β (Aβ) pathology in cognitively unimpaired (CU) older adults. However, the influence of subjective cognitive decline (SCD) severity on the association between Aβ and gait speed is not known.ObjectiveWe examined the relationship among gait speed, SCD severity and Aβ deposition in CU older adults.MethodsGait speed was measured over 15-feet. Aβ deposition was quantified using Pittsburgh-B (PiB) PET, expressed in Centiloid units (CL). Severity of SCD was quantified on the Memory Functioning Questionnaire (MFQ) on measures of seriousness and frequency of forgetting, mnemonic usage and retrospective functioning. We fitted a series of linear models with gait speed as the dependent variable; and each dichotomized sub-scale of the MFQ and Aβ as independent variables, adjusting for depression, white matter hyperintensity volume and executive function.ResultsIn 58 CU individuals (mean age 85, 35% female), mean gait speed was 0.91 m/s and Aβ deposition was 36 CL. The relationship between slower gait and greater Aβ deposition showed a stronger association in those with more frequent mnemonic use (r = -0.36, p = 0.05) and with greater seriousness of forgetting (r = -0.33, p = 0.08) compared to those with lesser severity of subjective cognitive concerns (r = 0.02, p = 0.9 and r = -0.08, p = 0.7 respectively).ConclusionsThe findings indicate that in those with greater severity of SCD, association between slower gait and greater Aβ deposition is stronger, warranting longitudinal assessments of SCD severity and gait changes in preclinical AD.

Indexed as

Amyloid beta-PeptidesBrainCognitive DysfunctionWalking SpeedAgedAged, 80 and overAniline CompoundsFemaleHumansMaleNeuropsychological TestsPositron-Emission TomographySeverity of Illness IndexAmyloid beta-PeptidesAniline CompoundsAlzheimer's diseaseamyloidgait speedolder adultssubjective cognitive decline

Identifiers

PMID40665692
PMCPMC12794807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.